Krystal Biotech (NASDAQ:KRYS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note released on Monday morning, Benzinga reports. They currently have a $200.00 target price on the stock. HC Wainwright also issued estimates for Krystal Biotech’s Q2 2024 earnings at $0.37 EPS, Q3 2024 earnings at $0.31 EPS, Q4 2024 earnings at $0.18 EPS and FY2024 earnings at $0.89 EPS.

Several other equities analysts have also recently weighed in on KRYS. Stifel Nicolaus reiterated a buy rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Guggenheim increased their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a research report on Tuesday, February 27th. William Blair reissued an outperform rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Finally, Citigroup raised their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a buy rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech has a consensus rating of Buy and an average target price of $171.00.

Krystal Biotech Trading Down 2.5 %

Shares of KRYS stock opened at $157.68 on Monday. The stock has a market capitalization of $4.50 billion, a P/E ratio of 1,971.25 and a beta of 0.91. The firm’s 50 day moving average is $168.76 and its 200 day moving average is $134.27. Krystal Biotech has a 12-month low of $86.03 and a 12-month high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to the consensus estimate of $47.37 million. During the same period in the prior year, the firm earned ($1.76) earnings per share. Krystal Biotech’s revenue for the quarter was up 452400.0% compared to the same quarter last year. As a group, equities analysts predict that Krystal Biotech will post 1.82 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The disclosure for this sale can be found here. Insiders sold a total of 38,087 shares of company stock valued at $6,210,591 over the last 90 days. Insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Hedge funds have recently modified their holdings of the company. Jennison Associates LLC grew its position in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after buying an additional 383,495 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at $14,272,000. Charles Schwab Investment Management Inc. boosted its position in shares of Krystal Biotech by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company’s stock worth $20,854,000 after purchasing an additional 17,614 shares in the last quarter. Vanguard Group Inc. grew its stake in Krystal Biotech by 40.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares during the last quarter. Finally, Trexquant Investment LP increased its position in Krystal Biotech by 8.8% during the 3rd quarter. Trexquant Investment LP now owns 8,113 shares of the company’s stock valued at $941,000 after buying an additional 657 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).